Literature DB >> 26244951

Russells Viper Envenomation-associated Acute Kidney Injury in Children in Southern India.

Sriram Krishnamurthy1, Kuralvanan Gunasekaran, Subramanian Mahadevan, Zachariah Bobby, Ajith Prabhu Kumar.   

Abstract

OBJECTIVE: To determine the frequency and risk factors of acute kidney injury in children with Russells viper envenomation using Acute Kidney Injury Network definition and classification system.
METHODS: A prospective observational study recruiting 61 subjects managed as per the National Snakebite Protocol.
RESULTS: 45.9% of envenomed children had acute kidney injury. The median (IQR) of the maximum serum creatinine level during hospitalization was 2 (1.3-4.8) mg/dL. The distribution of stages 1, 2 and 3 of acute kidney injury was 32.1%, 17.9% and 50% respectively. Dialysis was required in 35.7% of the children with acute kidney injury.
CONCLUSION: Acute kidney injury is common with Russells viper envenomation. Native treatments and bleeding manifestations were associated with acute kidney injury in our patient population.

Entities:  

Mesh:

Year:  2015        PMID: 26244951     DOI: 10.1007/s13312-015-0679-x

Source DB:  PubMed          Journal:  Indian Pediatr        ISSN: 0019-6061            Impact factor:   1.411


  3 in total

1.  Clinicopathological spectrum of snake bite-induced acute kidney injury from India.

Authors:  Sanjay Vikrant; Ajay Jaryal; Anupam Parashar
Journal:  World J Nephrol       Date:  2017-05-06

2.  Acute kidney failure following severe viper envenomation: clinical, biological and ultrasonographic aspects.

Authors:  Blaise Adelin Tchaou; Kofi-Mensa Savi de Tové; Charles Frédéric Tchégnonsi N'Vènonfon; Patrick Kouomboua Mfin; Abdou-Rahman Aguemon; Martin Chobli; Jean-Philippe Chippaux
Journal:  J Venom Anim Toxins Incl Trop Dis       Date:  2020-12-07

Review 3.  Bedside Coagulation Tests in Diagnosing Venom-Induced Consumption Coagulopathy in Snakebite.

Authors:  Supun Wedasingha; Geoffrey Isbister; Anjana Silva
Journal:  Toxins (Basel)       Date:  2020-09-10       Impact factor: 4.546

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.